Inmune Bio, Inc. INMB
Inmune Bio, Inc. (Nasdaq: INMB) is a rare genetic drug developer. Its lead program, CORDStrom, is in Phase 3 for Recessive Dystrophic Epidermolysis Bullosa (RDEB). Its next catalyst on record is CORDStrom: US BLA submission (10-K target; undated in later 10-Q) (December 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: CORDStrom — US BLA submission (10-K target; undated in later 10-Q) (December 2026). 7 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| CORDStrom | RDEB (pivotal blinded randomized cross-over MissionEB trial completed; marketing applications planned) | cell therapy | Phase 3 |
| INKmune | Metastatic castrate-resistant prostate cancer (open-label Phase II nearing completion) | cell therapy | Phase 2 |
| XPro1595 | Alzheimer's disease (Phase 2 completed 2025, missed primary endpoint; development halted pending partner) | protein/peptide | Phase 2 |
Recent results and decisions
- Oct 21, 2026submitted Final pre-MAA package submitted to UK MHRA on October 20, 2026.
today announced that it has submitted its final pre-Marketing Authorisation Application (pre-MAA) package to the UK Medicines and Healthcare products Regulatory Agency (MHRA)
Filing - Oct 21, 2026n/a INmune Bio entered into a Master Services Agreement with Uniphar to support international commercialization and named-patient access for Ebstrocel.
INmune Bio Inc. has entered into a Master Services Agreement with Uniphar Durbin Ireland Limited establishing a scalable framework to support international access, distribution and commercialization of Ebstrocel™.
Filing - Oct 20, 2026submitted INmune Bio submitted final pre-MAA package for Ebstrocel to UK MHRA on October 20, 2026, and plans full MAA submission in early February 2027.
The Company has submitted its final pre-Marketing Authorisation Application (pre-MAA) package to the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Ebstrocel™ (CORDStrom™).
Filing
7 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 rare genetic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.